CKD
Chronic kidney disease staging, CKD-MBD, cardiorenal syndrome, and KDIGO guideline updates, curated by ASNRT.
Browse all news
Explore the full ASNRT newsroom for society announcements, KDIGO guideline updates, AJNT issue releases, and notable developments across the breadth of nephrology.
Latest in this topic
The most recent evidence summaries curated by ASNRT on this topic:
Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis · Plant-dominant low-protein diet versus standard care in adults with chronic kidney disease stages 3-5: A randomized controlled trial protocol. · Finerenone in Type 1 Diabetes and Chronic Kidney Disease. · New Federal Dietary Guidelines Impact Chronic Kidney Disease Management With Tim Pflederer Md · Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in CKD · KDIGO Releases New Guideline For Anemia In Chronic Kidney Disease · Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists · Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis · Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. · Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) · Comparison of the renal outcomes of novel antidiabetic agents in type 2 diabetes with chronic kidney disease: a network meta-analysis · Contemporary management of advanced chronic kidney disease: An evidence-based review · Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD · Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions. · Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD · Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients - A systematic review and network meta-analysis · Pregnancy and Long-Term Kidney Function in CKD: A Systematic Review and Meta-Analysis. · Novel Potassium Binders for Hyperkalemia and Optimization of RAAS Inhibitor Therapy in CKD or Heart Failure: A Systematic Review and Meta-analysis · Preventing chronic kidney disease and maintaining kidney health: conclusions from a KDIGO Controversies Conference · KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know. · Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (CONFIDENCE) · Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease · Things We Do for No Reason™: Avoiding intravenous iodinated contrast material in patients with acute kidney injury or chronic kidney disease. · Perioperative Nitric Oxide Conditioning Reduces Acute Kidney Injury in Cardiac Surgery Patients with Chronic Kidney Disease (the DEFENDER Trial): A Randomized Controlled Trial · Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. · Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis. · Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline · Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials · Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. · Combination Therapy: An Upcoming Paradigm to Improve Kidney and Cardiovascular Outcomes in Chronic Kidney Disease · Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease · Chronic kidney disease. · Risk-directed management of chronic kidney disease · Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. · Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials · Endothelin receptor antagonists in chronic kidney disease. · The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. · KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. · Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. · Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?